Ceftriaxone-resistant viridans streptococci bacteraemia among patients treated at a large comprehensive cancer care centre: a retrospective eighteen-year study
Open Access
- 3 July 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 6 (4) , dlae126
Abstract
Viridans streptococci (VS) are opportunistic oral commensals and a common cause of bacteraemia in neutropenic patients. In this retrospective single centre cohort study, we investigated the prevalence of ceftriaxone resistance in VS (CRO-R VS) blood isolates between January 2005 and December 2022 from patients treated at a tertiary care hospital. Blood culture isolates were identified using biochemicals and mass spectrometry. Susceptibility testing was performed by Kirby–Bauer and Epsilometer tests. Demographic data, clinical outcomes and antimicrobial use were assessed through electronic medical record review. Among 791 patients with VS bacteraemia, 31 (4%) had confirmed CRO-R VS bacteraemia over the 18-year period; 20/31 (65%) were patients also treated at the Fred Hutchinson Cancer Center and were the focus of this study. Of these 20 patients, 18 (90%) had a known haematologic malignancy; 14 (70%) had undergone haematopoietic cell transplant (HCT); 18 (90%) were neutropenic at the time of culture. Two (10%) patients died within 30 days of CRO-R VS bacteraemia. All the CRO-R isolates (20/20) were members of the Streptococcus mitis group, 12 were multi-drug resistant; all were susceptible to vancomycin. Most patients received vancomycin once blood cultures were positive for a Gram-positive organism. During the study period, the frequency of VS isolate susceptibility testing increased; however, there was no concomitant increase in the percentage of CRO-R isolates at our facility. These data are important in an era where cefepime monotherapy is often used and reinforces the importance of routine resistance testing among VS bacteraemia.Keywords
Funding Information
- National Institutes of Health/National Cancer Institute (P30 CA15704)
This publication has 23 references indexed in Scilit:
- Third-generation cephalosporin and carbapenem resistance in Streptococcus mitis/oralis. Results from a nationwide registry in the NetherlandsClinical Microbiology and Infection, 2019
- Microbiology and clinical characteristics of viridans group streptococci in patients with cancerThe Brazilian Journal of Infectious Diseases, 2018
- Viridans group streptococci bloodstream infections in neutropenic adult patients with hematologic malignancy: Single center experienceFolia Microbiologica, 2017
- Bloodstream infections in neutropenic cancer patients: A practical updateVirulence, 2016
- Development and Validation of a Clinical Model to Predict the Presence of β-Lactam Resistance in Viridans Group Streptococci Causing Bacteremia in Neutropenic Cancer PatientsClinical Infectious Diseases, 2014
- The impact of a change in antibacterial prophylaxis from ceftazidime to levofloxacin in allogeneic hematopoietic cell transplantationBone Marrow Transplantation, 2009
- Antimicrobial Resistance of Community-acquired Bloodstream Isolates of Viridans Group StreptococciInfection, 2006
- Antimicrobial susceptibility of viridans group streptococcal blood isolates to eight antimicrobial agentsScandinavian Journal of Infectious Diseases, 2004
- Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin AmericaClinical Microbiology and Infection, 2001
- Bacteremia due to viridans streptococci in neutropenic patients: A reviewThe American Journal of Medicine, 1994